3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
CNS
1
Conditions
Multiple Myeloma
145
Lymphoma, Follicular
41
Lymphoma, Large B-Cell, Diffuse
36
Lymphoma, B-Cell, Marginal Zone
24
Recurrence
17
Lymphoma, Mantle-Cell
17
Lymphoma
16
Neoplasms, Plasma Cell
15
Lymphoma, Non-Hodgkin
15
Leukemia, Lymphocytic, Chronic, B-Cell
11
Neoplasms
9
Lymphoma, B-Cell
8
Smoldering Multiple Myeloma
7
Burkitt Lymphoma
5
Neoplasm, Residual
4
Leukemia, Plasma Cell
4
Waldenstrom Macroglobulinemia
3
Myelodysplastic Syndromes
3
Lymphoma, T-Cell, Peripheral
3
Lymphoma, T-Cell, Cutaneous
3
Plasmacytoma
2
Pancreatic Neoplasms
2
Neuroblastoma
2
Lymphoma, T-Cell
2
Leukemia, Myelomonocytic, Chronic
2
Leukemia, Myeloid, Acute
2
Leukemia
2
Hodgkin Disease
2
Hematologic Diseases
2
Urinary Bladder Neoplasms
1
Interventions
Magnetic Resonance Spectroscopy
8
Specimen Handling
7
Biopsy
6
X-Rays
5
Phantoms, Imaging
5
Temozolomide
4
Nuclear Medicine Department, Hospital
4
Nivolumab
4
Carboplatin
4
selpercatinib
3
larotrectinib
3
Topotecan
3
Etoposide
3
Cyclophosphamide
3
Cisplatin
3
Automobiles
3
tazemetostat
2
pembrolizumab
2
erdafitinib
2
entrectinib
2
ensartinib
2
cabozantinib
2
Vincristine
2
Surveys and Questionnaires
2
Radiotherapy
2
Radiosurgery
2
Radiation
2
Positron-Emission Tomography
2
Paclitaxel
2
ONC206
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Central Nervous System Neoplasms
×
Lenalidomide
×
1 year
×
Clear all
NCT04446962
2025-09-25
LOC-R01
Institut Curie
Phase 1/2
Active not recruiting
118 enrolled